What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Surgery
His primary areas of investigation include Multiple sclerosis, Internal medicine, Surgery, Magnetic resonance imaging and Central nervous system disease.
His study in Multiple sclerosis is interdisciplinary in nature, drawing from both Lesion, Pathology, White matter and Nuclear medicine.
The study incorporates disciplines such as Gastroenterology, Placebo, Placebo-controlled study and Cardiology in addition to Internal medicine.
The Surgery study combines topics in areas such as Interferon beta-1a, Adverse effect, Teriflunomide, Hazard ratio and Clinically isolated syndrome.
His study in the fields of Diffusion MRI under the domain of Magnetic resonance imaging overlaps with other disciplines such as In patient.
His studies deal with areas such as Predictive value of tests, Magnetization transfer, Radiology, Neurology and Optic neuritis as well as Central nervous system disease.
His most cited work include:
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis (1970 citations)
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (1618 citations)
- Defining the clinical course of multiple sclerosis: The 2013 revisions (1374 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Multiple sclerosis, Internal medicine, Neuroscience, Magnetic resonance imaging and Pathology.
His study looks at the relationship between Multiple sclerosis and topics such as Nuclear medicine, which overlap with Magnetization transfer.
His studies in Internal medicine integrate themes in fields like Surgery, Oncology, Gastroenterology, Expanded Disability Status Scale and Placebo.
His work deals with themes such as Clinical trial, Adverse effect, Randomized controlled trial, Teriflunomide and Cladribine, which intersect with Placebo.
His Magnetic resonance imaging study incorporates themes from Neurology and Neuroradiology.
His research investigates the connection with Pathology and areas like White matter which intersect with concerns in Corpus callosum, Atrophy and Audiology.
He most often published in these fields:
- Multiple sclerosis (49.87%)
- Internal medicine (26.55%)
- Neuroscience (16.24%)
What were the highlights of his more recent work (between 2018-2021)?
- Multiple sclerosis (49.87%)
- Internal medicine (26.55%)
- In patient (12.05%)
In recent papers he was focusing on the following fields of study:
Giancarlo Comi mainly investigates Multiple sclerosis, Internal medicine, In patient, Clinical trial and Disease.
His Multiple sclerosis research incorporates elements of Alemtuzumab, Cladribine, Magnetic resonance imaging, Neuroscience and Pediatrics.
His research integrates issues of Gastroenterology, Placebo, Expanded Disability Status Scale and Oncology in his study of Internal medicine.
His Placebo research is multidisciplinary, relying on both Tolerability, Teriflunomide and Phases of clinical research.
His work in Clinical trial is not limited to one particular discipline; it also encompasses Randomized controlled trial.
His Family medicine research includes themes of Clinical investigation and Ofatumumab.
Between 2018 and 2021, his most popular works were:
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial (58 citations)
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. (55 citations)
- Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders (50 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Gene
Multiple sclerosis, Internal medicine, Placebo, Disease and Expanded Disability Status Scale are his primary areas of study.
His Multiple sclerosis research is multidisciplinary, incorporating perspectives in Disease activity, White matter, Magnetic resonance imaging, Alemtuzumab and Pediatrics.
In his work, Young adult and Biomarker is strongly intertwined with Gastroenterology, which is a subfield of Internal medicine.
His Placebo research integrates issues from Tolerability, Adverse effect, Cladribine and Lymphocyte.
Giancarlo Comi has included themes like Connectome, Brain network and Epidemiology in his Disease study.
His Expanded Disability Status Scale research is multidisciplinary, relying on both Odds ratio, Clinical endpoint, Proportional hazards model, Age of onset and Cohort.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
